How Laurel Taylor Built A Company That Is Helping Crush Student Debt

Related Posts

08Oct

Silo Pharma achieves milestone – Partner Zylo Therapeutics Receive DEA Approval to Advance Silos time released Ketamine technology

Silo Pharma, Inc. a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their... read more
07Oct

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline... read more
18Jan

Myomo® to Present at Noble Capital Markets’ 15th Annual Investor Conference

Myomo, Inc., a wearable medical robotics company, today announced that it will be presenting at NobleCon15 - Noble Capital Markets’... read more
02Aug

LUMO Partners with Coastal Pet Products

Coastal Pet Products will served as a distribution partner​ for LUMO's Ridgeback Grooming Tool, which will be released at SuperZoo... read more
20Oct

Meet The New Unicorns Minted In September 2022

Twelve companies joined The Crunchbase Unicorn Board in September 2022, adding $19.6 billion in value to the board. These companies have... read more
30Apr

Pittsburgh biotech firm involved in development of potential COVID-19 treatment

CytoAgents, a Pittsburgh biotech firm, and Quotient Sciences, are accelerating development of a COVID-19 treatment. The treatment would focus on... read more
02Feb

Pain relief: In a Super Bowl first, both teams use sam® Sport

Scoop up the chili, fly with the Buffalo wings and pass the guacamole dip. For the first time in Super... read more
14Aug

Brisbane boy needs $25k for US trip that could give him whole new outlook

Now the Geoghegan family is hopeful that new technology will allow Max to finally see the big cats at Dreamworld,... read more
30Apr

Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system (ECS), today announced... read more
10Dec

Pittsburgh-based company behind ‘promising’ new COVID-19 treatment

On Wednesday, the Wolf Administration plans to highlight what it calls in a news advisory a “promising new drug candidate... read more